Jim Simons Tyme Technologies, Inc. Call Options Transaction History

Renaissance Technologies LLC

  • $63.1 Billion
  • Q3 2024

Call Options

0 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
No transaction found.

About TYME TECHNOLOGIES, INC.

TYME Quotes by TradingView
  • Ticker TYME
  • Exchange NASDAQ
  • Shares Outstandng 172,207,008
  • Description
  • Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also devel...
More about TYME
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email